Krintafel
(Tafenoquine)ApprovedSmall molecule
Tafenoquine is an antimalarial medication used in two ways: to prevent malaria from returning in people currently being treated with chloroquine or hydroxychloroquine, and to prevent malaria infection in travelers visiting areas where the disease is common. It works by killing the organisms that cause malaria.[2] Krintafel is currently approved and in use across 4 indications[4].[1]
Krintafel is one of 63 small molecule programs targeting Adult. It is currently in Approved.
4
Indications
31
Total Trials
6
Active Trials
62
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
4
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
127 competitors in Adult
#DrugCompanyPhaseTrials
1Krintafel
GGlaxo Dba Glaxosmithkline
Approved
Tebrazid
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase 3
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Mounjaro
Eli LillyPhase 2
Rifampicin
Boehringer IngelheimPhase 3
Myqorzo
CCytokinetics
Phase 3
Opzelura
DDizal Pharmaceuticals
Phase 2
Skyclarys
BiogenPhase 1
Sunlenca
GileadPhase 1
NM8074
NNovelMed Therapeutics
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Malaria4 trials
Show 1 more trial
Babesiosis3 trials
Plasmodium vivax malaria2 trials
13 more indications
Safety and Efficacy1 trial
Plasmodium Falciparum1 trial
Adult1 trial
Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults
Not yet recruiting·SState University of New York - Upstate Medical University·Phase 1·NCT07373743·20 enrolled
Oral1 trial
Hemolysis1 trial
Single Dose1 trial
Efficacy1 trial
Effectiveness1 trial
Efficacy and Safety1 trial
Unspecified8 trials
Show 5 more trials
Regulatory
FDA Approval Timeline[5]
Jul 20, 2018
KRINTAFEL
NDA NDA210795
Aug 8, 2018
ARAKODA
NDA NDA210607
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Krintafel drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Tafenoquine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- GGlaxo Dba Glaxosmithkline